Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 456906 in Healthy Japanese Males with High BMI
NCT04384081Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of survodutide in obesity (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Cumulative percentage of subjects withdrawn from up-titration by dose escalation scheme up to 113 days. Started Jun 2020; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04384081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04384081.